Showing results (21-30 of 182) with videos related to
Sort By:
Pageof 19
Neurodegenerative Disease Management|September 15, 2018
Identifying a new subtype of multiple sclerosisBruce D Trapp, Daniel OntanedaCNS Drugs|September 27, 2015
Risk Mitigation Strategies for Adverse Reactions Associated with the Disease-Modifying Drugs in Multiple SclerosisAdnan M Subei, Daniel OntanedaNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|October 5, 2016
Imaging as an Outcome Measure in Multiple SclerosisDaniel Ontaneda, Robert J FoxNeurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|August 4, 2017
The Role of Advanced Magnetic Resonance Imaging Techniques in Multiple Sclerosis Clinical TrialsKedar R Mahajan, Daniel OntanedaCurrent Opinion in Neurology|April 19, 2015
Progressive multiple sclerosisDaniel Ontaneda, Robert J FoxTherapeutic Advances in Drug Safety|August 2, 2014
Benefits versus risks of latest therapies in multiple sclerosis: a perspective reviewDaniel Ontaneda, Daniela Di CapuaExpert Review of Clinical Pharmacology|November 26, 2011
Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720)Daniel Ontaneda, Jeffrey A CohenDegenerative Neurological and Neuromuscular Disease|July 28, 2018
Treating primary-progressive multiple sclerosis: potential of ocrelizumab and review of B-cell therapiesJenny J Feng, Daniel OntanedaContinuum (Minneapolis, Minn.)|August 7, 2013
Multiple sclerosis treatment: risk mitigationDaniel Ontaneda, Robert J FoxThe International Journal of Neuroscience|October 12, 2013
Is neuromyelitis optica with advanced age of onset a paraneoplastic disorder?Daniel Ontaneda, Robert J FoxPageof 19